Christian Happi is affiliated with The Africa Centre of Excellence for Genomics of Infectious Diseases (ACEGID) at Redeemer's University Nigeria, Ede, Nigeria. He is a researcher in the field of infectious diseases, contributing significantly to the understanding and treatment of various viral infections.
Research Contributions
Christian Happi's research primarily focuses on the efficacy and safety of treatments for infectious diseases such as COVID-19. His work includes significant studies on the combination of nitazoxanide with ritonavir-boosted atazanavir for treating COVID-19. In addition, his contributions extend to deep sequencing methods for RNA viruses like Lassa and Ebola, highlighting his expertise in genomics and molecular virology. He also has research interests in antimalarial drug resistance, as evidenced by his work on antimalarial susceptibility in Gabon.
Aliases
Christian Happi is also known by other variations of his name, including C. Happi and Christian Ch Happi.
